Cutaneous Reactions to BRAF Inhibitors


BRAF inhibitors, specifically vemurafenib and dabrafenib, are emerging as first-line treatment for unresectable and/or metastatic BRAF mutated melanoma due to their superior efficacy and improved survival statistics. While better tolerated than previously used treatment options, they carry high rates of cutaneous reactions, with most BRAF-inhibitor treated patients experiencing at least one cutaneous adverse effect.

Photosensitivity, various skin rashes, skin papillomas, hyperkeratosis, verrucal keratoses, and cutaneous squamous cell carcinomas (SCCs) are some of the more common cutaneous toxicities reported to date. These are typically managed symptomatically without need for dose reduction or discontinuation of the BRAF inhibitor. MEK inhibitors are now being used in combination with BRAF inhibitors to improve efficacy, prevent drug resistance, and lower the rate of cutaneous reactions. This chapter focuses on the cutaneous reactions associated with the RAF inhibitor sorafenib and the BRAF inhibitors vemurafenib and dabrafenib.


BRAF inhibitor RAF inhibitor Metastatic melanoma Vemurafenib Dabrafenib 

Suggested Reading

  1. Anforth RM, Blumetti TC, Kefford RF, Sharma R, Scolyer RA, Kossard S, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol. 2012;167:1153–60.CrossRefPubMedGoogle Scholar
  2. Anforth R, Fernandez-Penas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 2013;14:e11–8.CrossRefPubMedGoogle Scholar
  3. Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, et al. Prospective study of cutaneous side effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24:1691–7.CrossRefPubMedGoogle Scholar
  4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.PubMedCentralCrossRefPubMedGoogle Scholar
  5. Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol. 2012;67(6):1265–72.CrossRefPubMedGoogle Scholar
  6. Falchook GS, Long GV, Kutzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastasis, and other solid tumors: a phase I dose-escalation trial. Lancet. 2012;379(9829):1893–901.PubMedCentralCrossRefPubMedGoogle Scholar
  7. Flaherty K, Infante JR, Falchook GS, et al. Phase I/II expansion cohort of BRAF inhibitor GSK2118436 + MEK inhibitor GSK1120212 in patients with BRAF mutant metastatic melanoma who progressed on a prior BRAF inhibitor. Pigment Cell Melanoma Res. 2012;25:E3.CrossRefGoogle Scholar
  8. Gelot P, Dutartre H, Khammari A, Boisrobert A, Schmitt C, Deybach JC, et al. Vemurafenib: an unusual UVA-induced photosensitivity. Exp Dermatol. 2013;22(4):297–8.CrossRefPubMedGoogle Scholar
  9. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65.CrossRefPubMedGoogle Scholar
  10. Huang V, Hepper D, Anadkat M, Cornelius L. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol. 2012;148(5):628–33.CrossRefPubMedGoogle Scholar
  11. Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15(4):436–44.CrossRefPubMedGoogle Scholar
  12. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with VAL600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicenter, open-label, phase 2 trial. Lancet Oncol. 2012;13:1087–95.CrossRefPubMedGoogle Scholar
  13. Mandala M, Massi D, DeGiorgi V. Cutaneous toxicities of BRAF inhibitors: clinical and pathological challenges and call to action. Clin Rev Oncol Hematol. 2013;88(2):318–37.CrossRefGoogle Scholar
  14. Martinez-Garcia M, Banerji U, Albanell J, Bahleda R, Dolly S, Kraeber-Bodéré F, et al. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res. 2012;18:4806–19.CrossRefPubMedGoogle Scholar
  15. Mattei PL, MB A l-P, Kraft S, Lawrence DP, Flaherty KT, Kimball AB. Cutaneous effects of BRAF inhibitor therapy: a case series. Ann Oncol. 2013;24:530–7.CrossRefPubMedGoogle Scholar
  16. McArthur GA, Chapman PB, Robert C. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3 randomised, open-label study. Lancet Oncol. 2014;15:323–32.PubMedCentralCrossRefPubMedGoogle Scholar
  17. Rinderknecht JD, Goldinger SM, Rozati S, Kamarashev J, Kerl K, French LE, et al. RASopathic skin eruptions during vemurafenib therapy. PLoS One. 2013;8(3):e58721.PubMedCentralCrossRefPubMedGoogle Scholar
  18. Sinha R, Edmonds K, Newton-Bishop JA, Gore ME, Larkin J, Fearfield L. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol. 2012;167:987–94.CrossRefPubMedGoogle Scholar
  19. Vanneste L, Wolter P, Van den Oord JJ, Stas M, Garmyn M. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients. J Eur Acad Dermatol Venereol. 2015;29(1):61–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  1. 1.DermatologyCollege Park Family Care CenterOverland ParkUSA
  2. 2.DermatologyUniversity of Kansas Medical CenterKansas CityUSA

Personalised recommendations